Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cantargia ABCHIX:CANTAS 33 Equity-to-Asset is 0.87 as of Mar. 2026, which is 1% below its 10-year median of 0.88. GuruFocus rates CHIX:CANTAS with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Cantargia AB ranks better than 77.26% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cantargia AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was kr234.0 Mil. Cantargia AB's Total Assets for the quarter that ended in Mar. 2026 was kr267.8 Mil.
Therefore, Cantargia AB's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.87.
The historical rank and industry rank for Cantargia AB's Equity-to-Asset or its related term are showing as below:
CHIX:CANTAs'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34 Med: 0.88 Max: 0.96
Current: 0.87
During the past 13 years, the highest Equity to Asset Ratio of Cantargia AB was 0.96. The lowest was 0.34. And the median was 0.88.
CHIX:CANTAs's Equity-to-Asset is ranked better than 77.26% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs CHIX:CANTAs: 0.87
Cantargia AB (CHIX:CANTAs) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cantargia AB Equity-to-Asset Related Terms
Cantargia AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cantargia AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Cantargia AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cantargia AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cantargia AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB (CHIX:CANTAS) has a Equity-to-Asset of 0.87 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cantargia AB and its competitors. This is near median its historical median of 0.88. Over the past decade, Cantargia AB's Equity-to-Asset has ranged from 0.34 to 0.96. According to the industry distribution chart, Cantargia AB ranks #322 out of 1416 companies in the Biotechnology industry, placing it in the top 22.7%.
Is Cantargia AB's Equity-to-Asset too high?
Cantargia AB's current Equity-to-Asset of 0.87 is near median its 10-year median of 0.88. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 0.96. The Biotechnology industry median Equity-to-Asset is 0.68. Cantargia AB's value of 0.87 is 27.9% above this industry median. Based on the distribution chart, Cantargia AB ranks #322 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cantargia AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #322 out of 1416 companies for Equity-to-Asset. This places Cantargia AB in the top 23% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Cantargia AB's value of 0.87 is 27.9% above this benchmark. Historically, Cantargia AB's own Equity-to-Asset has ranged from 0.34 to 0.96 over the past decade. While the company's 10-year median is 0.88 vs. the industry median of 0.68, Cantargia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantargia AB's current Equity-to-Asset of 0.87 is 27.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cantargia AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantargia AB's current Equity-to-Asset is 0.87, which is near median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current Equity-to-Asset of 0.87. The current Equity-to-Asset is 0.87, which is near median its 10-year median of 0.88 and 27.9% above the Biotechnology industry median of 0.68. Cantargia AB's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current Equity-to-Asset is 0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
33GF Score
Get the complete analysis for CHIX:CANTAS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
